lobbying_activities: 3433670

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
3433670	de89b2f0-8a99-417f-a068-d02e9ba4744c	Q3	EMERGENT BIOSOLUTIONS INC.	304931	EMERGENT BIOSOLUTIONS INC	2025	third_quarter	DIS	- Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act - Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY26 - Opioid crisis legislation, naloxone access and awareness - State opioid response (SOR) Grant funding FY26 - Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY26 - Tribal Opioid Response Grant funding for FY26 - NDAA for Fiscal Year 2025 and Fiscal Year 2026 - provisions related to biological and chemical defense and access to naloxone - H.R.1968, the Full-Year Continuing Appropriations and Extensions Act, 2025 - H.R.2483, SUPPORT for Patients and Communities Reauthorization Act of 2025 - H.R.5252, Having Overdoes Protection Equipment Act	Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office		530000	0	0	2025-10-15T11:29:22-04:00